Dox-containing adjuvant chemotherapy is recommended as the first line anti-cancer drug in 2016 NCCN’s breast cancer guidelines, especially for HER-2 positive and triple negative breast cancer patients5. This evidence concerns the gene ERBB2 and breast cancer.